The lab: Circulating Tumor biomarkers group
Lab's research themes:
The laboratory aims at investigating the clinical relevance of circulating tumor biomarkers that are related to the tumor dissemination and metastatic process.
Merits of the lab:
BTC lab, headed by Pr François-Clément Bidard, is one of the leading French labs for analyzing circulating tumor biomarkers, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA). The lab has a long track record in circulating tumor cells (CTCs) enumeration by Cellsearch system (Menarini) and circulating tumor DNA (ctDNA) detection by droplet-based digital PCR (ddPCR) and serves as a platform for real-time CTC and ctDNA assessment in several clinical trials (NCT04720729: MONDRIAN/Breast cancer, NCT04790682/LIBERTY LUNG/non-small cell lung cancer, NCT02866149: ALCINA/Breast cancer).
We have demonstrated that the CTC count might be used as a reliable biomarker method for guiding the choice between chemotherapy and endocrine therapy as the first-line treatment in hormone receptor–positive, ERBB2-negative metastatic breast cancer (JAMA Oncol. 2021 Jan 1;7(1):34-41.) and in most patients, resistance-associated mutations (ESR1 mutation) in the estrogen receptor gene can be detected and targeted before tumor progression (NCT03079011: PADA-1 trial/Breast cancer) which allows the optimization of the endocrine therapy partner of CDK4/6 [cyclin-dependent kinase 4 and 6] inhibitor”.
Why do we want medical doctors?
Prof. François-Clément Bidard is an oncologist working at Institut Curie and the University of Versailles, France. Currently, several clinical assays are ongoing in the laboratory. A recruited MD-PhD EMERALD fellow will quickly integrate into the projects, enforce these connections with the biologists in the wet-lab and benefit from this joint environment.
The position

What’s the main purpose of our research?
The project that we would like to propose for MD-PhD programme EMERALD is to monitor the treatment efficiency of immunotherapy by tracing ctDNA in plasma from metastatic non-small cell lung cancer patients (NSCLC) (LibertyLung, NCT04790682) or triple-negative breast cancer patients (ALCINA4, NCT05088395) who are eligible for immune checkpoint inhibitors treatments and to predict the relapse.
How we will do it?
The blood samples will be collected before and after treatments till relapse. Cell free circulating DNA (cfcDNA) will be extracted and ctDNA will be quantified with ddPCR by targeting the somatic mutations detected in tumor DNA from the same patient by next generation sequencing. Following this, the associations between ctDNA detection and the patients’ outcomes will be evaluated.
Why is this important?
This project will allow us to validate the correlation of ctDNA changes with response and survival to immune checkpoint inhibitors in metastatic NSCLC, receiving immunotherapy in the first-line setting, with a follow-up all during the duration of treatment, in a sufficiently large cohort (n=220) to provide a high level of evidence for designing subsequent, interventional studies. In breast cancer patients, this study will allow us to monitor the treatment efficiency of immune checkpoint inhibitors in a small cohort of triple-negative breast cancer patients (n=80) to have preliminary results.
Who is a good fit for the project?
Experience in oncology and interest in liquid biopsy, circulating tumor biomarkers and its clinical relevance.

Other positions
- IDIBAPS#4 – Mechanisms involved in strenuous exercise-induced atrial myocardial fibrosisDavid Brena2022-06-02T10:51:50+00:00
IDIBAPS#4 – Mechanisms involved in strenuous exercise-induced atrial myocardial fibrosis
- IC#4 – The role polyglutamylation in tauopathic neurodegenerationDavid Brena2022-05-18T16:35:32+00:00
IC#4 – The role polyglutamylation in tauopathic neurodegeneration
- IC#3 – Evaluation of the efficiency of immunotherapy by tracing ctDNA in metastatic NSCLC and triple-negative breast cancer patientsDavid Brena2022-05-18T16:17:43+00:00
IC#3 – Evaluation of the efficiency of immunotherapy by tracing ctDNA in metastatic NSCLC and triple-negative breast cancer patients
- IC#2 – New targetable vulnerabilities for the treatment of chemoresistant breast and ovarian BRCA1/2-mutated tumorsDavid Brena2022-05-25T10:09:18+00:00
IC#2 – New targetable vulnerabilities for the treatment of chemoresistant breast and ovarian BRCA1/2-mutated tumors
- IDIBAPS#3 – Mechanisms involved in vascular inflammation/remodeling in systemic vasculitisDavid Brena2022-05-17T10:38:48+00:00
IDIBAPS#3 – Mechanisms involved in vascular inflammation/remodeling in systemic vasculitis
- IDIBAPS#2 – Mechanisms and therapies for Myeloma, amyloidosis, macroglobulinemia and other gammapathiesDavid Brena2022-05-24T08:49:06+00:00
IDIBAPS#2 – Mechanisms and therapies for Myeloma, amyloidosis, macroglobulinemia and other gammapathies
- IDIBAPS#1 – Developing and investigating computing, machine learning and physiological modelling for understanding each individual heart towards personalised medicineDavid Brena2022-05-17T10:37:53+00:00
IDIBAPS#1 – Developing and investigating computing, machine learning and physiological modelling for understanding each individual heart towards personalised medicine
- BRIC#6 – Tumour evolution, heterogeneity, and understanding of the mutational processes leading to aggressive diseaseDavid Brena2022-05-12T16:57:52+00:00
BRIC#6 – Tumour evolution, heterogeneity, and understanding of the mutational processes leading to aggressive disease
- IC#1 – The role of RNASE1 in lung metastatic niche establishment by breast cancer cellsemerald_SCS2022-05-17T13:59:30+00:00
IC#1 – The role of RNASE1 in lung metastatic niche establishment by breast cancer cells
- MDC#3 – Neuromuscular and Cardiovascular Cell Biologyemerald_SCS2022-05-17T12:04:54+00:00
MDC#3 – Neuromuscular and Cardiovascular Cell Biology
- MDC#2 – Molecular and cellular basis of behavioremerald_SCS2022-05-17T12:05:10+00:00
MDC#2 – Molecular and cellular basis of behavior
- MDC#1 – Host-microbiome factors in cardiovascular diseaseemerald_SCS2022-05-17T12:05:25+00:00
MDC#1 – Host-microbiome factors in cardiovascular disease
- NKI#1 – Epigenetic regulation in hormone-driven cancers and therapy resistanceemerald_SCS2022-05-19T08:58:30+00:00
NKI#1 – Epigenetic regulation in hormone-driven cancers and therapy resistance
- VIB#8 – Mechanisms of inflammation and associated tissue damage in musculoskeletal diseasesemerald_SCS2022-05-16T20:44:33+00:00
VIB#8 – Mechanisms of inflammation and associated tissue damage in musculoskeletal diseases
- VIB#7 – Endothelial immunosuppressive mystery genes for alternative immunotherapy: artificial intelligence-driven target discovery and validationemerald_SCS2022-05-16T20:32:47+00:00
VIB#7 – Endothelial immunosuppressive mystery genes for alternative immunotherapy: artificial intelligence-driven target discovery and validation
- VIB#6 – Cellular metabolism and metabolic regulation in cancer metastasisemerald_SCS2022-05-18T08:52:10+00:00
VIB#6 – Cellular metabolism and metabolic regulation in cancer metastasis
- VIB#5 – Unraveling the molecular mechanisms of neuronal degeneration in motor neuron diseasesemerald_SCS2022-05-16T19:39:35+00:00
VIB#5 – Unraveling the molecular mechanisms of neuronal degeneration in motor neuron diseases
- VIB#4 – Identification of universal biomarkers of metastatic melanoma in CTCsemerald_SCS2022-05-18T08:43:51+00:00
VIB#4 – Identification of universal biomarkers of metastatic melanoma in CTCs
- VIB#3 – Basic mechanisms of Alzheimer’s disease and neurodegenerationemerald_SCS2022-05-16T19:54:56+00:00
VIB#3 – Basic mechanisms of Alzheimer’s disease and neurodegeneration
- VIB#2 – Integrative genomics to underpinning somatic evolution, tumour heterogeneity, and treatment resistanceemerald_SCS2022-05-15T23:07:12+00:00
VIB#2 – Integrative genomics to underpinning somatic evolution, tumour heterogeneity, and treatment resistance
- VIB#1 – Medical biotechnology to improve hepatocellular carcinoma diagnosticsemerald_SCS2022-05-24T08:33:04+00:00
VIB#1 – Medical biotechnology to improve hepatocellular carcinoma diagnostics
- BRIC#5 – The impact of severe maternal respiratory tract infections on fetal brain development and offspring behavioremerald_SCS2022-05-19T18:49:58+00:00
BRIC#5 – The impact of severe maternal respiratory tract infections on fetal brain development and offspring behavior
- BRIC#7 – Understanding and overcoming drug resistance in acute myeloid leukemiaemerald_SCS2022-05-24T08:43:03+00:00
BRIC#7 – Understanding and overcoming drug resistance in acute myeloid leukemia